{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:12:57Z","timestamp":1793776377694,"version":"4.6.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Reliable detection of amyloid pathology is essential for Alzheimer\u2019s disease (AD) diagnosis and treatment. We directly compared routine ELISA assays and the automated Lumipulse platform against quantitative amyloid PET in a real-world memory clinic cohort. In 153 participants, flutemetamol amyloid PET and CSF biomarkers were assessed across platforms. Concordance with PET and predictors of discordance were evaluated. PET visual reads and Centiloids showed near-perfect agreement (AUC\u2009=\u20090.99). The p-tau181\/A\u03b242 ratio achieved the highest concordance with PET (OPA 87% ELISA, 92% Lumipulse), while the Lumipulse A\u03b242\/40 ratio reached 93%. About 6% of participants showed consistent discordance between CSF and PET, associated with APOE \u03b54 and mixed or non-AD pathologies. Automated CSF assays align strongly with amyloid PET and support biomarker standardization. Persistent discrepancies between CSF and PET likely reflect underlying biological heterogeneity such as mixed or non-AD pathologies and APOE \u03b54 carriage.<\/jats:p>","DOI":"10.1038\/s41598-025-23759-5","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:33:27Z","timestamp":1763134407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Concordance between amyloid PET and CSF biomarkers in clinical setting: a cross-platform comparison and in-depth analysis of discordant cases"],"prefix":"10.1038","volume":"15","author":[{"given":"Ji\u0159\u00ed","family":"Cerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad\u00e9la","family":"\u0160korvagov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Vyhn\u00e1lek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate\u0159ina","family":"Veverov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Dvo\u0159\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0160t\u011bp\u00e1n","family":"Koz\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ale\u0161","family":"Kavka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Hort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"23759_CR1","doi-asserted-by":"publisher","unstructured":"Jack Jr., C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.13859 (2024).","DOI":"10.1002\/alz.13859"},{"issue":"4","key":"23759_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack, C. R. et al. NIA-AA research framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. J. Alzheimers Assoc. 14(4), 535\u2013562 (2018).","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"issue":"3","key":"23759_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings, J. et al. Lecanemab: Appropriate use recommendations. J. Prev. Alzheimers Dis. 10(3), 362\u2013377 (2023).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"23759_CR4","doi-asserted-by":"crossref","unstructured":"Donanemab: Appropriate use recommendations. J. Prev. Alzheimers Dis. 12(5), 100150 (2025).","DOI":"10.1016\/j.tjpad.2025.100150"},{"key":"23759_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.dadm.2017.06.001","volume":"9","author":"S Salloway","year":"2017","unstructured":"Salloway, S. et al. Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer\u2019s disease. Alzheimers Dement. Amst. Neth. 9, 25\u201334 (2017).","journal-title":"Alzheimers Dement. Amst. Neth."},{"key":"23759_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.nicl.2016.11.008","volume":"13","author":"SW Seo","year":"2017","unstructured":"Seo, S. W. et al. Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. NeuroImage Clin. 13, 130\u2013137 (2017).","journal-title":"NeuroImage Clin."},{"issue":"8","key":"23759_CR7","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark, C. M. et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study. Lancet Neurol. 11(8), 669\u2013678 (2012).","journal-title":"Lancet Neurol."},{"issue":"6","key":"23759_CR8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(6), 512\u2013527 (2023).","journal-title":"JAMA"},{"issue":"10","key":"23759_CR9","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jalz.2018.04.011","volume":"14","author":"BJ Hanseeuw","year":"2018","unstructured":"Hanseeuw, B. J. et al. PET staging of amyloidosis using striatum. Alzheimers Dement. 14(10), 1281\u20131292 (2018).","journal-title":"Alzheimers Dement."},{"issue":"1","key":"23759_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk, W. E. et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. J. Alzheimers Assoc. 11(1), 1-15.e1-4 (2015).","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"issue":"1","key":"23759_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13550-018-0456-7","volume":"8","author":"MR Battle","year":"2018","unstructured":"Battle, M. R. et al. Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods. EJNMMI Res. 8(1), 107 (2018).","journal-title":"EJNMMI Res."},{"issue":"2","key":"23759_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie, R. et al. Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology. Alzheimers Dement. J. Alzheimers Assoc. 15(2), 205\u2013216 (2019).","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"23759_CR13","doi-asserted-by":"crossref","unstructured":"Hanseeuw, B. J., Malotaux, V., Dricot, L., Quenon, L., Sznajer, Y, Cerman, J. et al. Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study. Eur. J. Nucl. Med. Mol. Imaging. (2020). https:\/\/pubmed.ncbi.nlm.nih.gov\/32601802\/.","DOI":"10.1007\/s00259-020-04942-4"},{"key":"23759_CR14","doi-asserted-by":"crossref","unstructured":"van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388(1), 9\u201321 (2023).","DOI":"10.1056\/NEJMoa2212948"},{"key":"23759_CR15","doi-asserted-by":"crossref","unstructured":"Farrar, G., Weber, C. J., Rabinovici, G. D. Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer\u2019s Association Research Roundtable. J. Prev. Alzheimers Dis. 12(1), 100008 (2025).","DOI":"10.1016\/j.tjpad.2024.100008"},{"issue":"6","key":"23759_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100784","volume":"9","author":"SJB Vos","year":"2014","unstructured":"Vos, S. J. B. et al. Variability of CSF Alzheimer\u2019s disease biomarkers: implications for clinical practice. PLoS ONE 9(6), e100784 (2014).","journal-title":"PLoS ONE"},{"issue":"4","key":"23759_CR17","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jalz.2011.05.2243","volume":"7","author":"N Mattsson","year":"2011","unstructured":"Mattsson, N. et al. The Alzheimer\u2019s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 7(4), 386-395.e6 (2011).","journal-title":"Alzheimers Dement."},{"key":"23759_CR18","doi-asserted-by":"crossref","unstructured":"Verwey, N. A., van der Flier, W. M., Blennow, K., Clark, C., Sokolow, S., De Deyn, P. P., et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer\u2019s disease. Ann. Clin. Biochem. 46(3), 235\u2013240 (2009).","DOI":"10.1258\/acb.2009.008232"},{"issue":"1","key":"23759_CR19","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1177\/13872877251314886","volume":"104","author":"SA Park","year":"2025","unstructured":"Park, S. A. et al. Comparative analysis of Elecsys and ELISA for differentiating amyloid-PET status in a Korean memory clinic based on cerebrospinal fluid biomarkers. J. Alzheimers Dis. JAD. 104(1), 232\u2013244 (2025).","journal-title":"J. Alzheimers Dis. JAD."},{"issue":"13","key":"23759_CR20","doi-asserted-by":"publisher","first-page":"6891","DOI":"10.3390\/ijms23136891","volume":"23","author":"A Orellana","year":"2022","unstructured":"Orellana, A. et al. Establishing in-house cutoffs of CSF Alzheimer\u2019s disease biomarkers for the AT(N) stratification of the Alzheimer Center Barcelona Cohort. Int. J. Mol. Sci. 23(13), 6891 (2022).","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"23759_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3233\/JAD-131838","volume":"41","author":"M Sauv\u00e9e","year":"2014","unstructured":"Sauv\u00e9e, M. et al. Additional use of A\u03b2\u2084\u2082\/A\u03b2\u2084\u2080 ratio with cerebrospinal fluid biomarkers P-tau and A\u03b2\u2084\u2082 increases the level of evidence of Alzheimer\u2019s disease pathophysiological process in routine practice. J. Alzheimers Dis. JAD. 41(2), 377\u2013386 (2014).","journal-title":"J. Alzheimers Dis. JAD."},{"issue":"3","key":"23759_CR22","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan, A. M. et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 59(3), 512\u2013519 (2006).","journal-title":"Ann Neurol."},{"issue":"11","key":"23759_CR23","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.jalz.2018.01.013","volume":"14","author":"SE Schindler","year":"2018","unstructured":"Schindler, S. E. et al. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement. J. Alzheimers Assoc. 14(11), 1460\u20131469 (2018).","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"issue":"6","key":"23759_CR24","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/ana.23908","volume":"74","author":"SM Landau","year":"2013","unstructured":"Landau, S. M. et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of \u03b2-amyloid. Ann. Neurol. 74(6), 826\u2013836 (2013).","journal-title":"Ann. Neurol."},{"key":"23759_CR25","doi-asserted-by":"crossref","unstructured":"Reimand, J., de Wilde, A., Teunissen, C. E., Zwan, M., Windhorst, A. D., Boellaard, R., et al. PET and CSF amyloid-\u03b2 status are differently predicted by patient features: information from discordant cases. Alzheimers Res. Ther. 11(1), 100 (2019).","DOI":"10.1186\/s13195-019-0561-5"},{"issue":"3","key":"23759_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jalz.2013.01.010","volume":"9","author":"N Mattsson","year":"2013","unstructured":"Mattsson, N. et al. CSF biomarker variability in the Alzheimer\u2019s Association quality control program. Alzheimers Dement. 9(3), 251\u2013261 (2013).","journal-title":"Alzheimers Dement."},{"issue":"1","key":"23759_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1212\/WNL.0000000000002081","volume":"86","author":"MD Zwan","year":"2016","unstructured":"Zwan, M. D. et al. Use of amyloid-PET to determine cutpoints for CSF markers. Neurology 86(1), 50\u201358 (2016).","journal-title":"Neurology"},{"issue":"1","key":"23759_CR28","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1038\/s41467-024-47971-5","volume":"15","author":"L Karlsson","year":"2024","unstructured":"Karlsson, L. et al. Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases. Nat. Commun. 15(1), 3676 (2024).","journal-title":"Nat. Commun."},{"issue":"1","key":"23759_CR29","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/s41598-024-83281-y","volume":"15","author":"S Mravinacov\u00e1","year":"2025","unstructured":"Mravinacov\u00e1, S. et al. Addressing inter individual variability in CSF levels of brain derived proteins across neurodegenerative diseases. Sci. Rep. 15(1), 668 (2025).","journal-title":"Sci. Rep."},{"issue":"1","key":"23759_CR30","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209419","volume":"103","author":"SE Mastenbroek","year":"2024","unstructured":"Mastenbroek, S. E. et al. Continuous \u03b2-amyloid CSF\/PET imbalance model to capture alzheimer disease heterogeneity. Neurology 103(1), e209419 (2024).","journal-title":"Neurology"},{"issue":"5","key":"23759_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.eurger.2010.07.012","volume":"1","author":"M Woodward","year":"2010","unstructured":"Woodward, M., MacKenzie, I. R. A., Hsiung, G. Y. R., Jacova, C. & Feldman, H. Multiple brain pathologies in dementia are common. Eur. Geriatr. Med. 1(5), 259\u2013265 (2010).","journal-title":"Eur. Geriatr. Med."},{"issue":"5","key":"23759_CR32","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1017\/S0317167100015316","volume":"39","author":"BW Wang","year":"2012","unstructured":"Wang, B. W. et al. Multiple pathologies are common in Alzheimer patients in clinical trials. Can. J. Neurol. Sci. J. Can. Sci. Neurol. 39(5), 592\u2013599 (2012).","journal-title":"Can. J. Neurol. Sci. J. Can. Sci. Neurol."},{"issue":"5","key":"23759_CR33","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41591-024-02931-w","volume":"30","author":"J Fortea","year":"2024","unstructured":"Fortea, J. et al. APOE4 homozygosity represents a distinct genetic form of Alzheimer\u2019s disease. Nat. Med. 30(5), 1284\u20131291 (2024).","journal-title":"Nat. Med."},{"issue":"5","key":"23759_CR34","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.neurobiolaging.2007.08.019","volume":"30","author":"L Glodzik-Sobanska","year":"2009","unstructured":"Glodzik-Sobanska, L. et al. The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer\u2019s disease. Neurobiol. Aging. 30(5), 672\u2013681 (2009).","journal-title":"Neurobiol. Aging."},{"issue":"15","key":"23759_CR35","doi-asserted-by":"publisher","first-page":"e1640","DOI":"10.1212\/WNL.0000000000200953","volume":"99","author":"BD Greenberg","year":"2022","unstructured":"Greenberg, B. D. et al. CSF Alzheimer disease biomarkers. Neurology 99(15), e1640\u2013e1650 (2022).","journal-title":"Neurology"},{"key":"23759_CR36","doi-asserted-by":"publisher","first-page":"1390620","DOI":"10.1155\/2016\/1390620","volume":"2016","author":"JA Monge-Argil\u00e9s","year":"2016","unstructured":"Monge-Argil\u00e9s, J. A. et al. Influence of APOE genotype on Alzheimer\u2019s disease CSF biomarkers in a Spanish population. BioMed. Res. Int. 2016, 1390620 (2016).","journal-title":"BioMed. Res. Int."},{"issue":"1","key":"23759_CR37","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00406-023-01701-y","volume":"275","author":"N Guill\u00e9n","year":"2025","unstructured":"Guill\u00e9n, N. et al. Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study. Eur. Arch Psychiatry Clin. Neurosci. 275(1), 257\u2013266 (2025).","journal-title":"Eur. Arch Psychiatry Clin. Neurosci."},{"issue":"1","key":"23759_CR38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13195-020-00767-3","volume":"13","author":"S Moon","year":"2021","unstructured":"Moon, S. et al. Alzheimer\u2019s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans. Alzheimers Res. Ther. 13(1), 22 (2021).","journal-title":"Alzheimers Res. Ther."},{"issue":"1","key":"23759_CR39","volume":"13","author":"EAJ Willemse","year":"2021","unstructured":"Willemse, E. A. J. et al. Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. Alzheimers Dement. Diagn. Assess. Dis. Monit. 13(1), e12182 (2021).","journal-title":"Alzheimers Dement. Diagn. Assess. Dis. Monit."},{"issue":"11","key":"23759_CR40","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","volume":"14","author":"O Hansson","year":"2018","unstructured":"Hansson, O. et al. CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. J. Alzheimers Assoc. 14(11), 1470\u20131481 (2018).","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"issue":"1","key":"23759_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12190","volume":"13","author":"MR Campbell","year":"2021","unstructured":"Campbell, M. R. et al. P-tau\/A\u03b242 and A\u03b242\/40 ratios in CSF are equally predictive of amyloid PET status. Alzheimers Dement. Amst. Neth. 13(1), e12190 (2021).","journal-title":"Alzheimers Dement. Amst. Neth."},{"issue":"9","key":"23759_CR42","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/acn3.50873","volume":"6","author":"D Alcolea","year":"2019","unstructured":"Alcolea, D. et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer\u2019s disease on Lumipulse. Ann. Clin. Transl. Neurol. 6(9), 1815\u20131824 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"23759_CR43","doi-asserted-by":"publisher","first-page":"173","DOI":"10.14735\/amcsnn2020173","volume":"83","author":"J Cerman","year":"2020","unstructured":"Cerman, J. et al. Cerebrospinal fluid ratio of phosphorylated tau protein and beta amyloid predicts amyloid pet positivity. Ceska Slov Neurol. Neurochir. 83(2), 173\u2013179 (2020).","journal-title":"Ceska Slov Neurol. Neurochir."},{"key":"23759_CR44","doi-asserted-by":"crossref","unstructured":"Sheardova, K., Vyhn\u00e1lek, M., Nedelska, Z., Laczo, J., Andel, R., Marciniak, R., et al. Czech Brain Aging Study (CBAS): Prospective multicentre cohort study on risk and protective factors for dementia in the Czech Republic. BMJ Open. 9(12).","DOI":"10.1136\/bmjopen-2019-030379"},{"key":"23759_CR45","doi-asserted-by":"crossref","unstructured":"Petersen, R. C. Mild cognitive impairment. Contin Lifelong Learn Neurol. 22(2, Dementia), 404\u2013418 (2016).","DOI":"10.1212\/CON.0000000000000313"},{"issue":"3","key":"23759_CR46","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7(3), 270\u2013279 (2011).","journal-title":"Alzheimers Dement."},{"issue":"3","key":"23759_CR47","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7(3), 263\u2013269 (2011).","journal-title":"Alzheimers Dement."},{"issue":"6","key":"23759_CR48","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen, F. et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease. Alzheimers Dement. J. Alzheimers Assoc. 10(6), 844\u2013852 (2014).","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"issue":"9","key":"23759_CR49","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky, K. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134(9), 2456\u20132477 (2011).","journal-title":"Brain"},{"issue":"11","key":"23759_CR50","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini, M. L. et al. Classification of primary progressive aphasia and its variants. Neurology 76(11), 1006\u20131014 (2011).","journal-title":"Neurology"},{"issue":"6","key":"23759_CR51","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU Hoglinger","year":"2017","unstructured":"Hoglinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov. Disord. Off. J. Mov. Disord. Soc. 32(6), 853\u2013864 (2017).","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"1","key":"23759_CR52","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 89(1), 88\u2013100 (2017).","journal-title":"Neurology"},{"issue":"2","key":"23759_CR53","first-page":"92","volume":"12","author":"DA Regier","year":"2013","unstructured":"Regier, D. A., Kuhl, E. A. & Kupfer, D. J. The DSM-5: Classification and criteria changes. World Psychiatry Off. J. World Psychiatr. Assoc. WPA. 12(2), 92\u201398 (2013).","journal-title":"World Psychiatry Off. J. World Psychiatr. Assoc. WPA."},{"issue":"2","key":"23759_CR54","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00259-018-4140-y","volume":"46","author":"O Belohlavek","year":"2019","unstructured":"Belohlavek, O., Jaruskova, M., Skopalova, M., Szarazova, G. & Simonova, K. Improved beta-amyloid PET reproducibility using two-phase acquisition and grey matter delineation. Eur. J. Nucl. Med. Mol. Imaging. 46(2), 297\u2013303 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"issue":"1","key":"23759_CR55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jalz.2011.07.004","volume":"8","author":"H Vanderstichele","year":"2012","unstructured":"Vanderstichele, H. et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer\u2019s disease diagnosis: a consensus paper from the Alzheimer\u2019s Biomarkers Standardization Initiative. Alzheimers Dement. J. Alzheimers Assoc. 8(1), 65\u201373 (2012).","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"issue":"2","key":"23759_CR56","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1515\/cclm-2021-0651","volume":"60","author":"J Gobom","year":"2022","unstructured":"Gobom, J. et al. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clin. Chem. Lab. Med. 60(2), 207\u2013219 (2022).","journal-title":"Clin. Chem. Lab. Med."},{"issue":"1","key":"23759_CR57","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13195-020-00587-5","volume":"12","author":"S Amadoru","year":"2020","unstructured":"Amadoru, S. et al. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer\u2019s disease. Alzheimers Res. Ther. 12(1), 22 (2020).","journal-title":"Alzheimers Res. Ther."},{"issue":"6","key":"23759_CR58","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/joim.12816","volume":"284","author":"K Blennow","year":"2018","unstructured":"Blennow, K. & Zetterberg, H. Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future. J. Intern. Med. 284(6), 643\u2013663 (2018).","journal-title":"J. Intern. Med."},{"issue":"7","key":"23759_CR59","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1007\/s00259-020-05174-2","volume":"48","author":"LE Collij","year":"2021","unstructured":"Collij, L. E. et al. Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent. Eur. J. Nucl. Med. Mol. Imaging. 48(7), 2169\u20132182 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"issue":"1","key":"23759_CR60","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13195-021-00836-1","volume":"13","author":"SK Royse","year":"2021","unstructured":"Royse, S. K. et al. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. Alzheimers Res. Ther. 13(1), 99 (2021).","journal-title":"Alzheimers Res. Ther."},{"issue":"4","key":"23759_CR61","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","volume":"19","author":"MS Rafii","year":"2023","unstructured":"Rafii, M. S. et al. The AHEAD 3\u201345 study: Design of a prevention trial for Alzheimer\u2019s disease. Alzheimers Dement. J. Alzheimers Assoc. 19(4), 1227\u20131233 (2023).","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"issue":"12","key":"23759_CR62","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.3390\/ph17121648","volume":"17","author":"A Jovalekic","year":"2024","unstructured":"Jovalekic, A. et al. Experiences from clinical research and routine use of florbetaben amyloid PET\u2014A decade of post-authorization insights. Pharmaceuticals. 17(12), 1648 (2024).","journal-title":"Pharmaceuticals."},{"issue":"5","key":"23759_CR63","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1159\/000539884","volume":"53","author":"KG Rothenberg","year":"2024","unstructured":"Rothenberg, K. G. et al. Cerebral amyloid angiopathy in patients with cognitive impairment: cerebrospinal fluid biomarkers. Dement. Geriatr. Cogn. Disord. 53(5), 248\u2013254 (2024).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"issue":"3","key":"23759_CR64","doi-asserted-by":"publisher","first-page":"fcad159","DOI":"10.1093\/braincomms\/fcad159","volume":"5","author":"JA Sembill","year":"2023","unstructured":"Sembill, J. A. et al. Cerebrospinal fluid biomarkers for cerebral amyloid angiopathy. Brain Commun. 5(3), fcad159 (2023).","journal-title":"Brain Commun."},{"key":"23759_CR65","doi-asserted-by":"publisher","unstructured":"Margraf, N. G., Jensen-Kondering, U., Weiler, C., Leypoldt, F., Maetzler, W., Philippen, S., et al. Cerebrospinal fluid biomarkers in cerebral amyloid angiopathy: New data and quantitative meta-analysis. Front. Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2022.783996\/full","DOI":"10.3389\/fnagi.2022.783996\/full"},{"issue":"1","key":"23759_CR66","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1177\/23969873241260538","volume":"10","author":"A Theodorou","year":"2025","unstructured":"Theodorou, A. et al. CSF and plasma biomarkers in cerebral amyloid angiopathy: A single-center study and a systematic review\/meta-analysis. Eur. Stroke J. 10(1), 278\u2013288 (2025).","journal-title":"Eur. Stroke J."},{"issue":"8","key":"23759_CR67","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.3390\/biomedicines12081781","volume":"12","author":"N Giagkou","year":"2024","unstructured":"Giagkou, N., Kapsali, I., Brinia, M. E. & Constantinides, V. C. Cerebrospinal fluid total and phosphorylated tau protein in behavioral variant frontotemporal dementia, progressive supranuclear palsy, corticobasal syndrome and non-fluent agrammatic primary progressive aphasia: a systematic review and meta-analysis. Biomedicines 12(8), 1781 (2024).","journal-title":"Biomedicines"},{"issue":"11","key":"23759_CR68","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele, R. et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat. Med. 28(11), 2381\u20132387 (2022).","journal-title":"Nat. Med."},{"issue":"10","key":"23759_CR69","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1007\/s00259-025-07270-7","volume":"52","author":"GD Kolinger","year":"2025","unstructured":"Kolinger, G. D. et al. Quantification of baseline amyloid PET in individuals with subjective cognitive decline can identify risk of amyloid accumulation and cognitive worsening: the FACEHBI study. Eur. J. Nucl. Med. Mol. Imaging. 52(10), 3578\u20133590 (2025).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"23759_CR70","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13195-019-0532-x","volume":"11","author":"A de Wilde","year":"2019","unstructured":"de Wilde, A. et al. Discordant amyloid-\u03b2 PET and CSF biomarkers and its clinical consequences. Alzheimers Res. Ther. 11, 78 (2019).","journal-title":"Alzheimers Res. Ther."},{"issue":"1","key":"23759_CR71","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S1474-4422(20)30412-9","volume":"20","author":"A Serrano-Pozo","year":"2021","unstructured":"Serrano-Pozo, A., Das, S. & Hyman, B. T. APOE and Alzheimer\u2019s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 20(1), 68\u201380 (2021).","journal-title":"Lancet Neurol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23759-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23759-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23759-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:03:19Z","timestamp":1763136199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23759-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23759"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23759-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6994563\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee for Multi-Centric Clinical Trials of the University Hospital Motol and 2nd Faculty of Medicine, Charles University in Prague, reference number: EK-1380\/22. All participants gave their written informed consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39963"}}